Anagin is developing first-in-class small molecule modulators of the excitatory neurotransmitter signaling complex. These protein signaling complexes play important roles in neuronal functions and disorders. Anagin’s novel therapeutic strategy is designed to interrupt NMDAR-dependent signaling while reducing or eliminating unwanted side effects, such as learning and memory deficits, hallucinations & ataxia.
Our novel small molecules reduce excessive nitric oxide production in specific regions of the brain in the presence of fear or injury.
Read a Related Blog Post
The human mind has evolved to feel fear during and after traumatic situations. Our sense of fear enables the body to make quick changes to either avoid or defend itself against the threat. Known as the “flight or fight” response, it is the initial healthy reaction to perceived danger that nearly everyone will experience to some extent during their lifetime. However, for some individuals, the emotional and physical response to danger persists long after the situation has ended. An individual’s response to perceived danger manifests in an array of symptoms that may lead to a diagnosis of Post Traumatic Stress Disorder and have an adverse impact to their quality of life.
Currently, there is no satisfactory treatment for PTSD. Patients who experience PTSD frequently have symptoms such as depression, anxiety, addiction, and mood swings. As a result, patients are treated with antidepressants, antianxiety, and other medications focused on alleviating these symptoms.
Despite the high personal and financial burden to individual patients and society, currently approved medications, such as selective serotonin reuptake inhibitors (SSRIs), solely treat the PTSD symptoms, not the underlying cause, offering only partial relief in fewer than 60% of the patients.
Rather than treating the symptoms, Anagin’s approach is focused on treating the underlying cause of PTSD by correcting the brain’s ongoing fear response without adverse side effects and thus vastly improve patient outcomes.Contact Anagin